Search

Displaying results 2001 - 2010 of 10000 in total
  1. Drug

    Trolamine

    go.drugbank.com/drugs/DB13747
    ApprovedInvestigational

    It is commonly used as a pH adjuster and surfactant in industrial and cosmetic products such as skin and hair conditioning products. … Trolamine contains small amounts of diethanolamine and ethanolamine and may also act as an antioxidant against the auto-oxidation of animal and vegetable fats [A27174].

  2. Drug

    Brompheniramine

    go.drugbank.com/drugs/DB00835
    Approved

    Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.

    Mixtures: M-end Wc, M-end PESynonyms: 3-(p-bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine, 3-(4-bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine
  3. Drug

    Fluciclovine (18F)

    go.drugbank.com/drugs/DB13146
    ApprovedInvestigational

    It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging. … [A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]

  4. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. … [A232955] In clinical trials, avalglucosidase alfa improved lung function in patients with Pompe disease.

  5. Drug

    Plecanatide

    go.drugbank.com/drugs/DB13170
    ApprovedInvestigational

    It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age … Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).

  6. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. … Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase

  7. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    episodes in patients with hemophilia A. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]

  8. Drug

    Glycopyrronium

    go.drugbank.com/drugs/DB00986
    ApprovedInvestigationalVet approved

    [A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers. … [A233565] Glycopyrronium was originally granted FDA approval on 11 August 1961.[L33090]

  9. Drug

    Silver citrate

    go.drugbank.com/drugs/DB11233
    Approved

    Mixtures: All-Natural Pen Spray
  10. Drug

    Simeprevir

    go.drugbank.com/drugs/DB06290
    ApprovedWithdrawn

    Since the viral protease NS3/4A complex is essential for cleaving the HCV encoded polyprotein into individual viral proteins facilitating replication [A19632], the drug blocks the viral replication process … Sustained virologic response 12 weeks after planned end of treatment (SVR12) was achieved in 170/176 (97%) subjects without cirrhosis treated with 12 weeks simeprevir in combination with sofosbuvir (FDA